Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248199 | 0.88 | GPR119 (0.52) | USP30GPR119NPC1ALDH1A1MAPT | |
| SCHEMBL5870827 | 0.83 | USP30 (0.52) | USP30GPR119NPC1ALDH1A1MAPT | |
| SCHEMBL3279406 | 0.82 | LCK (0.61) | NPC1HTTRAB9ALCKJAK2 | |
| SCHEMBL13400113 | 0.82 | LCK (0.61) | NPC1HTTRAB9ALCKJAK2 | |
| SCHEMBL3272471 | 0.82 | LCK (0.61) | NPC1HTTRAB9ALCKJAK2 | |
| SCHEMBL13400114 | 0.82 | LCK (0.61) | NPC1HTTRAB9ALCKJAK2 | |
| SCHEMBL13400095 | 0.82 | LCK (0.61) | NPC1HTTRAB9ALCKJAK2 | |
| SCHEMBL3276669 | 0.82 | LCK (0.61) | NPC1HTTRAB9ALCKJAK2 | |
| SCHEMBL3271587 | 0.82 | LCK (0.61) | NPC1HTTRAB9ALCKJAK2 | |
| SCHEMBL20970042 | 0.81 | USP30 (0.62) | USP30GPR119NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7692019-B2 | Methods for the stereoselective synthesis of substituted piperidines | SEPRACOR INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692019-B2 | Methods for the stereoselective synthesis of substituted piperidines | SEPRACOR INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7129228-B2 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060211864-A1 | Methods for the stereoselective synthesis of substituted piperidines | AQUILA BRIAN M | 2006-09-21 | — | — | US | disclosed |
| US-7005524-B2 | Methods for the stereoselective synthesis of substituted piperidines | SEPRACOR INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20040235893-A1 | Methods for the stereoselective synthesis of substituted piperidines | AQUILA BRIAN M (US) | 2004-11-25 | — | — | US | disclosed |
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | CUNY GREGORY D (US) | 2004-10-21 | — | — | US | disclosed |
| US-6703508-B2 | ANALGESICS | SEPRACOR, INC. | 2004-03-09 | — | — | US | disclosed |
| US-6677332-B1 | AMIDE-SUBSTITUTED PIPERIDINE OR AZEPINE DERIVATIVES TO TREAT DRUG ABUSE AND TINNITUS | SEPRACOR, INC. | 2004-01-13 | — | — | US | disclosed |
| US-6645980-B1 | Ligands for biological receptors such as opiate receptors or G-protein coupled receptors used for treating pain, drug dependence or tinnitus in mammals | SEPRACOR INC. | 2003-11-11 | — | — | US | disclosed |
| US-6635661-B2 | Piperidinyl amide compounds | SEPRACOR INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020177721-A1 | Methods for the stereoselective synthesis of substituted piperidines | SEPRACOR INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209846-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | USP30 3782/4885GPR119 697/4885NPC1 2369/4885 |
| US-20040235893-A1 | Methods for the stereoselective synthesis of substituted piperidines | OPRK1, OPRL1, HTR5A | USP30 3436/4885GPR119 1275/4885NPC1 1093/4885 |
| US-20060211864-A1 | Methods for the stereoselective synthesis of substituted piperidines | OPRK1, OPRL1, HTR5A | USP30 3436/4885GPR119 1275/4885NPC1 1093/4885 |
| US-20020177721-A1 | Methods for the stereoselective synthesis of substituted piperidines | OPRK1, OPRL1, HTR5A | USP30 3436/4885GPR119 1275/4885NPC1 1093/4885 |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | USP30 3782/4885GPR119 697/4885NPC1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.